摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-O-p-nitrobenzoyl-2,3,5-tri-O-benzyl-β-D-ribofuranose | 51450-29-4

中文名称
——
中文别名
——
英文名称
1-O-p-nitrobenzoyl-2,3,5-tri-O-benzyl-β-D-ribofuranose
英文别名
2,3,5-tri-O-benzyl-O-(p-nitrobenzoyl)-β-D-ribose;2,3,5-tri-O-benzyl-1-O-(p-nitrobenzoyl)-β-D-ribofuranose;2,3,5-Tri-O-benzyl-1-O-<4-nitro-benzoyl>-β-D-ribose;1-O-p-nitrobenzoyl-2,3,5-tri-O-benzyl-beta-D-ribofuranose;[(2S,3R,4R,5R)-3,4-bis(phenylmethoxy)-5-(phenylmethoxymethyl)oxolan-2-yl] 4-nitrobenzoate
1-O-p-nitrobenzoyl-2,3,5-tri-O-benzyl-β-D-ribofuranose化学式
CAS
51450-29-4
化学式
C33H31NO8
mdl
——
分子量
569.611
InChiKey
VBDBDZHLJKDSSB-BEMMEUOBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.6
  • 重原子数:
    42
  • 可旋转键数:
    13
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    109
  • 氢给体数:
    0
  • 氢受体数:
    8

反应信息

点击查看最新优质反应信息

文献信息

  • Polysubstituted benzimidazoles as antiviral agents
    申请人:The Regents of the University of Michigan
    公开号:US05646125A1
    公开(公告)日:1997-07-08
    This invention relates to novel polysubstituted benzimidazoles and compositions and their use in the treatment of viral infections. The polysubstituted benzimidazoles and compositions of the present invention exhibit antiviral properties against viruses of the herpes family, particularly human cytomegalovirus (HCMV) and herpes simplex viruses (HSV).
    本发明涉及新型多取代苯并咪唑及其组合物,以及它们在治疗病毒感染方面的应用。本发明的多取代苯并咪唑和组合物对疱疹病毒家族的病毒,尤其是人类巨细胞病毒(HCMV)和单纯疱疹病毒(HSV)表现出抗病毒特性。
  • Treatment of herpes infections with polysubstituted benzimidazoles
    申请人:The Regents of the University of Michigan
    公开号:US05712255A1
    公开(公告)日:1998-01-27
    A method for treating a herpes viral infection comprising administering to the infected host a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or formulation thereof, selected from the group consisting of compounds having the following formula: ##STR1## wherein: R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Br and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 52 in the text); R.sub.1 is H, R.sub.2 is NO.sub.2, R.sub.3 is NO.sub.2, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 61 in the text); R.sub.1 is Cl, R.sub.2 is H, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 81 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is I and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 83a in the text); R.sub.1 is Br, R.sub.2 is Br, R.sub.3 is H, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 85 in the text); R.sub.1 is H, R.sub.2 is Br, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 95 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Br, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 99 in the text); R.sub.1 is H, R.sub.2 is I, R.sub.3 is I, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is .beta.-D-ribofuranosyl (denoted compound 107 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Cl and R.sub.6 is 2'-deoxy-.beta.-D-erythro-pentofuranosyl (denoted compound 111 in the text); R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is Br and R.sub.6 is 2'-deoxy-.beta.-D-erythro-pentofuranosyl (denoted compound 112 in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is Cl and R.sub.6 is (1,3-dihydroxy-2-propoxy)methyl (denoted compound 155 in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is NH.sub.2 and R.sub.6 is (1,3-dihydroxy-2-propoxy)methyl (denoted compound 156 in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is OCH.sub.3 and R.sub.6 is 2-hydroxyethoxymethyl (denoted compound 166a in the text); R.sub.1 is Cl, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is Cl, R.sub.5 is NH.sub.2 and R.sub.6 is 2-hydroxyethoxymethyl (denoted compound 167 in the text); and R.sub.1 is H, R.sub.2 is Cl, R.sub.3 is Cl, R.sub.4 is H, R.sub.5 is NH.sub.2 and R.sub.6 is benzyl (denoted compound 182 in the text).
    一种治疗单纯疱疹病毒感染的方法,包括向受感染宿主投与以下化合物中的一种,或其在药学上可接受的盐或制剂,所述化合物具有以下公式: ##STR1## 其中:R.sub.1为H,R.sub.2为Cl,R.sub.3为Cl,R.sub.4为H,R.sub.5为Br,R.sub.6为β-D-核糖呋喃(在文本中标记为化合物52);R.sub.1为H,R.sub.2为NO.sub.2,R.sub.3为NO.sub.2,R.sub.4为H,R.sub.5为Cl,R.sub.6为β-D-核糖呋喃(在文本中标记为化合物61);R.sub.1为Cl,R.sub.2为H,R.sub.3为Cl,R.sub.4为H,R.sub.5为Cl,R.sub.6为β-D-核糖呋喃(在文本中标记为化合物81);R.sub.1为H,R.sub.2为Cl,R.sub.3为Cl,R.sub.4为H,R.sub.5为I,R.sub.6为β-D-核糖呋喃(在文本中标记为化合物83a);R.sub.1为Br,R.sub.2为Br,R.sub.3为H,R.sub.4为H,R.sub.5为Cl,R.sub.6为β-D-核糖呋喃(在文本中标记为化合物85);R.sub.1为H,R.sub.2为Br,R.sub.3为Cl,R.sub.4为H,R.sub.5为Cl,R.sub.6为β-D-核糖呋喃(在文本中标记为化合物95);R.sub.1为H,R.sub.2为Cl,R.sub.3为Br,R.sub.4为H,R.sub.5为Cl,R.sub.6为β-D-核糖呋喃(在文本中标记为化合物99);R.sub.1为H,R.sub.2为I,R.sub.3为I,R.sub.4为H,R.sub.5为Cl,R.sub.6为β-D-核糖呋喃(在文本中标记为化合物107);R.sub.1为H,R.sub.2为Cl,R.sub.3为Cl,R.sub.4为H,R.sub.5为Cl,R.sub.6为2'-脱氧-β-D-erythro-戊呋喃核苷(在文本中标记为化合物111);R.sub.1为H,R.sub.2为Cl,R.sub.3为Cl,R.sub.4为H,R.sub.5为Br,R.sub.6为2'-脱氧-β-D-erythro-戊呋喃核苷(在文本中标记为化合物112);R.sub.1为Cl,R.sub.2为Cl,R.sub.3为Cl,R.sub.4为Cl,R.sub.5为Cl,R.sub.6为(1,3-二羟基-2-丙氧基)甲基(在文本中标记为化合物155);R.sub.1为Cl,R.sub.2为Cl,R.sub.3为Cl,R.sub.4为Cl,R.sub.5为NH.sub.2,R.sub.6为(1,3-二羟基-2-丙氧基)甲基(在文本中标记为化合物156);R.sub.1为Cl,R.sub.2为Cl,R.sub.3为Cl,R.sub.4为Cl,R.sub.5为OCH.sub.3,R.sub.6为2-羟基乙氧基甲基(在文本中标记为化合物166a);R.sub.1为Cl,R.sub.2为Cl,R.sub.3为Cl,R.sub.4为Cl,R.sub.5为NH.sub.2,R.sub.6为2-羟基乙氧基甲基(在文本中标记为化合物167);R.sub.1为H,R.sub.2为Cl,R.sub.3为Cl,R.sub.4为H,R.sub.5为NH.sub.2,R.sub.6为苄基(在文本中标记为化合物182)。
  • Heras, Federico G. de las; Fernandez-Resa, Piedad, Journal of the Chemical Society. Perkin transactions I, 1982, p. 903 - 908
    作者:Heras, Federico G. de las、Fernandez-Resa, Piedad
    DOI:——
    日期:——
  • Alkynylation of mixed acetals with organotin acetylides
    作者:Dongguan. Zhai、Weixu. Zhai、Robert M. Williams
    DOI:10.1021/ja00216a025
    日期:1988.4
  • ZHAI, DONGGUAN;ZHAI, WEIXU;WILLIAMS, ROBERT M., J. AMER. CHEM. SOC., 110,(1988) N 8, 2501-2505
    作者:ZHAI, DONGGUAN、ZHAI, WEIXU、WILLIAMS, ROBERT M.
    DOI:——
    日期:——
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐